A, Simplified decay scheme of 89Zr (data taken from the National Nuclear Data Center: www.nndc.bnl.gov), B, schematic overview of 89Zr-labeled antibody using DFO as chelator, and C, biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer (reprinted with permission from Dijkers EC, et al Clinical Pharmacology & Therapeutics 2010; 87: 586–592)